SZ2001

SZ2001 is an orally active, small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) under development by Suzhong Pharmaceutical Group. It is primarily indicated for the treatment of renal anemia associated with chronic kidney disease (CKD). The drug works by inhibiting the prolyl hydroxylase enzymes that normally degrade hypoxia-inducible factor (HIF) under normoxic conditions. By stabilizing HIF, SZ2001 mimics the physiological response to hypoxia, leading to increased endogenous erythropoietin production, improved iron mobilization, and enhanced erythropoiesis. As of 2024, it is in Phase 2 clinical trials in China, targeting patients with non-dialysis-dependent chronic kidney disease (NDD-CKD).